BETA
Your AI-Trained Oncology Knowledge Connection!
Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.
TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma
Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.
FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer
The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.
NCCN Guidelines Add LEMS Antibody Testing for SCLC
Symptom specificity is now included in updated guidelines for SCLC relating to LEMS, characterized by proximal muscle weakness and autonomic dysfunction.
Finding the Best Setting for Bispecific T-Cell Engagers in Multiple Myeloma
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma
The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.
Identifying Limitations to CAR T-Cell Therapies in Large B-Cell Lymphoma
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk
Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.
FDA Grants Accelerated Approval to Dordaviprone in Diffuse Midline Glioma
Supporting data for the accelerated approval of dordaviprone come from 5 open-label trials in H3 K27M-mutant diffuse midline glioma.
Creating a Seamless Transition from Pediatric to Adult Patient Cancer Care
While there is no clear and cut way to transition patients from pediatric to adult care, Maria C. Velez, MD, has established a helpful network of willing clinicians.
FDA OKs Intravenous Tocilizumab Biosimilar in Cytokine Release Syndrome
The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.
Differentiating T-Cell Engager Use Vs Standard Therapy in Multiple Myeloma
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
IDMC Recommends Continuation of ELI-002 7P Trial in PDAC
The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.
Highlighting Bispecific Use Across Multiple Myeloma Indications
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
New ASPHO President Hopes to Increase Awareness Around Pediatric Oncology
While Maria C. Velez, MD’s, term as president of ASPHO is only 1 year, she is already confident in ASPHO’s strategic plans.
FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL
Results from the marginal zone lymphoma cohort of the TRANSCEND FL trial showed liso-cel elicited an ORR of 95.5% and a CR rate of 62.1%.
TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care
At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.
Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission
Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.
Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma
More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.
Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC
Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.
FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma
The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana, LLC.
INKmune Exhibits Favorable Safety in Metastatic CRPC
Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.
Looking Towards the Future of Peritoneal Surface Malignancy Care
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.
Outlining Next Steps for Tarlatamab in Early-Line ES-SCLC and Beyond
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
Enhanced Representation Is Key in New Peritoneal Surface Malignancy Guidelines
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
Aumolertinib Has Long-Term Survival Benefit in NSCLC With Brain Metastases
Nonrandomized phase 2 data support further assessment of aumolertinib among patients with NSCLC and brain metastases in a randomized clinical trial.
Tarlatamab Provides Clinicians New Immunologic Option in SCLC
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
National ICE-T Conference Aims to Make CAR T Safer and More Available
Leading experts gathered in Orlando, Florida, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.
Dato-DXd Shows Favorable Benefit in EGFR-Mutant NSCLC
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
![“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9b290688648a249e516474c175a3c06309426d15-2950x1568.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.")
